WormBase Tree Display for Disease_model_annotation: WBDOannot00001421
expand all nodes | collapse all nodes | view schema
| WBDOannot00001421 | Disease_term | DOID:10652 | |
|---|---|---|---|
| Disease_of_species | Homo sapiens | ||
| Modeled_by | Strain | WBStrain00056368 | |
| Association_type | is_model_of | ||
| Evidence_code | GO_code | IMP | |
| ECO_term | ECO:0007013 | ||
| Modifier_info | Modifier_molecule | WBMol:00003989 | |
| WBMol:00001874 | |||
| Modifier_association_type | condition_ameliorated_by | ||
| Genetic_sex | hermaphrodite | ||
| Paper_evidence | WBPaper00066270 | ||
| Disease_model_description | In Alzheimers disease patients, amyloid-beta plaques are found embedded in the extracellular matrix and surrounded by collagens, which might hinder antibodies from targeting the plaques. A transgenic C. elegans strain, LSD2104, expressing fluorescent human A-beta (1-42) acts as an in vivo model for secreted amyloid aggregation in the extracellular matrix. The use of the antibiotic, rifampicin (75 microM) together with the flavonoid, quercetin (350 microM) in this model had the maximum effect in clearing the extracellular amyloid plaque burden compared to either drug alone. | ||
| Curator_confirmed | WBPerson324 | ||
| Date_last_updated | 03 Jan 2024 00:00:00 |
